Definium Therapeutics (DFTX) Interest Expenses (2023 - 2026)

Definium Therapeutics (DFTX) has reported Interest Expenses for 7 consecutive years, with $58.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 9659395.85% year-over-year to $58.2 billion; the TTM figure through Mar 2026 stood at $58.2 billion (up 2372407.75% YoY), while the FY2025 annual figure was $30.9 billion, up 645.12% from the prior year.
• Interest Expenses climbed to $58.2 billion in Q1 2026 per DFTX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $58.2 billion in Q1 2026 and bottomed at $76000.0 in Q1 2023.
• Historically, Interest Expenses has averaged $4.0 billion across 5 years, with a median of $820000.0 in 2023.
• Annual changes were most pronounced in 2023 — Interest Expenses slumped 99.2% — and 2026, when it soared 9659395.85%.
• Definium Therapeutics' Interest Expenses stood at $36.1 million in 2022, then sank by 97.73% to $820000.0 in 2023, then slipped by 20.0% to $656000.0 in 2024, then soared by 71.34% to $1.1 million in 2025, then surged by 5173402.22% to $58.2 billion in 2026.
• Business Quant data shows DFTX's Interest Expenses at $58.2 billion in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.